Anti-Trust Approval Received for Acquisition of CLOSURE Medical Corporation by Johnson & Johnson

Anti-Trust Approval Received for Acquisition of CLOSURE Medical
Corporation by Johnson & Johnson 


RALEIGH, N.C., May 2  /PRNewswire-FirstCall/ -- CLOSURE Medical Corporation
(NASDAQ:CLSR) today announced that the U.S. Federal Trade Commission had
granted early termination of the waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act with respect to the previously-announced acquisition
of CLOSURE Medical Corporation by Johnson & Johnson.  The proposed transaction
is expected to close as promptly as possible after CLOSURE Medical's special
meeting of stockholders, which is scheduled to be held on June 2, 2005, subject
to the remaining closing conditions.

About CLOSURE Medical Corporation

CLOSURE Medical Corporation is a global leader in the development and
manufacture of innovative biomaterial-based medical devices that fulfill the
needs of healthcare practitioners, patients and consumers.

For additional information on CLOSURE Medical visit its website at
http://www.closuremed.com/.

This release includes forward-looking statements that are based on assumptions
about many important factors, including the approval by CLOSURE stockholders of
the acquisition; general industry and market conditions; general domestic and
international economic conditions, such as interest rate and currency exchange
rate fluctuations; technological advances and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approvals and the factors listed in CLOSURE's most recent 10-K.  As such, they
involve risks that could cause actual results to differ materially.  The
Company does not undertake to update its forward-looking statements.

This material is not a substitute for the proxy statement CLOSURE Medical has
filed with the Securities and Exchange Commission and is currently mailing to
stockholders.  Investors are urged to read the proxy statement, including
detailed risk factors, because it contains important information.  The proxy
statement and other documents filed by CLOSURE Medical with the Securities and
Exchange Commission are available free of charge at the SEC's website,
http://www.sec.gov/, or by visiting CLOSURE Medical's website at
http://www.closuremed.com/.

CLOSURE Medical and certain of its directors, executive officers and certain
other members of its management may be deemed to be soliciting proxies from
CLOSURE Medical's shareholders in connection with the proposed transaction. 
Investors may obtain a detailed list of names, affiliations and interests of
CLOSURE Medical participants in the solicitation of proxies of CLOSURE
Medical's shareholders by reading the proxy statement. 

DATASOURCE: CLOSURE Medical Corporation



CONTACT:  investors, Joe Allen, [phone], , or

media, Len Hall, [phone], , both of Allen & Caron

Inc, for CLOSURE Medical Corporation; or Benny Ward, CFO of CLOSURE Medical

Corporation, [phone]



Web site:  http://www.closuremed.com/ 

Copyright